Our results suggest that IBD patients with genetic variants associated with high TNF inflammatory response were more likely to respond to anti-TNF treatment, whereas IBD patients with genetic variants associated with high IL-1β, IL-6 or INFγ were more likely to be non-responders [13]. The gene discussed is IL6; the disease is inflammatory bowel disease.